Other languages Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
3.3 ^USD	-2.37%		-6.52%	-54.79%

06-26	Repare Therapeutics Says Lunresertib With Folfiri Shows 'Promising' Efficacy, Tolerability in Phase 1 Solid Tumor Study	MT
06-26	Repare Therapeutics Inc. Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Repare Therapeutics Says Lunresertib With Folfiri Shows 'Promising' Efficacy, Tolerability in Phase 1 Solid Tumor Study	06-26
Repare Therapeutics Inc. Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI	06-26
Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib	06-12
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion Trial	06-10
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of Tresr Clinical Trial	06-10
Repare Therapeutics Gets Fast-Track Designation for Cancer Treatment Combo Candidate	06-04
Repare Therapeutics Inc. Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer	06-04
Top Premarket Gainers	05-08
Repare Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07
DEBIOPHARM ET REPARE THERAPEUTICS ANNONCENT LE TRAITEMENT D’UN PREMIER PATIENT DANS LE CADRE DE L’ÉTUDE DE PHASE 1/1B MYTHIC ÉVALUANT LA COMBINATION D’INHIBITEURS WEE1 ET PKMYT1 GÉNÉRANT UNE LÉTHALITÉ SYNTHÉTIQUE	04-30
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of Wee1 and Pkmyt1 Inhibition	04-30
Repare Therapeutics Inc. Announces Directorate Changes	04-26
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664	02-15
Repare Therapeutics to Regain Global Rights to Oncology Therapy Camonsertib After Termination of Collaboration With Roche	02-13
Repare Therapeutics Inc. and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer	01-04
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: Rp-1664, an Oral Plk4 Inhibitor, and Rp-3467, an Oral Pol Inhibitor	11-15
Repare Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Repare Therapeutics Reports 'Positive Initial Data' From Trial for Lunresertib	13/10/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Other languages

Filters